Development of bozepinib-loaded nanocapsules for nose-to-brain delivery: preclinical evaluation in glioblastoma
| Autor: | Ana Maria Oliveira Battastini, Franciele Aline Bruinsmann, Ana Conejo-García, Luiz Fernando Lopes Silva, Danieli Rosane Dallemole, Joaquín M. Campos, Amanda de Fraga Dias, Silvia Stanisçuaski Guterres, Adriana Raffin Pohlmann, Olga Cruz-Lopez, Fabrício Figueiró |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Temozolomide
Chemistry Biomedical Engineering Medicine (miscellaneous) Brain Bioengineering Development medicine.disease Nanocapsules Oxazepines In vivo Purines Glioma Cell Line Tumor Drug delivery medicine Cancer research Zeta potential Distribution (pharmacology) Humans General Materials Science Viability assay Glioblastoma medicine.drug |
| Zdroj: | Nanomedicine (London, England). 16(23) |
| ISSN: | 1748-6963 |
| Popis: | Aim: To develop and characterize bozepinib-loaded lipid-core nanocapsules (BZP-LNC+) as a potential treatment for glioblastoma (GBM). Methods: Characterization of nanocapsules was performed by diameter, polydispersity index, Zeta potential, pH and encapsulation efficiency. GBM cell viability, cell cycle and Annexin/PI were evaluated after BZP-LNC+ treatment. Synergism between BZP-LNC+ and temozolomide (TMZ) was performed by CompuSyn software and confirmed in vitro and in vivo. Results: BZP-LNC+ showed adequate particle sizes, positive Zeta potential, narrow size distribution and high encapsulation efficiency. BZP-LNC+ reduces GBM growth by inducing apoptosis. BZP-LNC+ and TMZ showed synergistic effect in vitro and reduced the in vivo glioma growth by approximately 81%. Conclusion: The present study provides proof-of-principle insights for the combination of these drugs for GBM treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|